Topics

IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck’s Keytruda® in DLBCL

07:05 EDT 3 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Abstract on the study accepted at the 2019 ICML Meeting IMV Inc. (Nasdaq: IMV; TSX: IMV), the clinical stage immuno-oncology corporation, today announced that the 2019 International Conference on Malignant Lymphoma (ICML) wi...

Other Sources for this Article

MEDIA
Andrea Cohen, Sam Brown Inc.
O: (917) 209-7163 E: andreacohen@sambrown.com

INVESTOR RELATIONS
Marc Jasmin, IMV Senior Director, Investor Relations and Communications
O: (902) 492-1819 ext: 1042
M: (514) 917-9481 E: mjasmin@imv-inc.com

NEXT ARTICLE

More From BioPortfolio on "IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck’s Keytruda® in DLBCL"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...